Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: January 15, 2026
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document does not contain a financial statement or performance metrics for the period.
Material Changes
No material changes to financial performance or operations are disclosed in this filing. The document serves primarily as a notification regarding unquoted securities.
Guidance, Outlook, and Risks
Management Commentary: None provided in this filing.
Risks and Contingencies: The filing incorporates by reference into Registration Statements on Form S-8 and Form F-3. The primary disclosure is the submission of Exhibit 99.1, a "Notification regarding unquoted securities - ATH."
Investor Verification Checklist
- Verify the details of the unquoted securities referenced in Exhibit 99.1.
- Review the referenced Registration Statements (Form S-8 and Form F-3) for broader context on capital structure and securities offerings.
- Confirm the company's status as a development stage enterprise and the implications for future revenue generation.